Moreover, Sehhoon Park et al. reported that durvalumab plus tremelimumab and definitive CCRT had promising efficacy in LA-ESCC patients, especially with high PD-L1 expression, which showed a superior 24-month OS rate compared with ours (85.7% vs. 31.2%).29 Overall, patients with poor response to chemotherapy/chemoimmunotherapy in our study exhibited lower sensitivity to radiation and had a prognosis inferior to those who initially received combined chemo(immuno)therapy and radiotherapy. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.